פמוזול Izrael - hebrejski - Ministry of Health

פמוזול

perrigo israel agencies ltd - letrozole 2.5 mg - film coated tablets - letrozole - • femozol (letrozole tablets) is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer . • femozol is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy .• extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy .• adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer .

אנסטרוזול מדיטק 1 מ"ג Izrael - hebrejski - Ministry of Health

אנסטרוזול מדיטק 1 מ"ג

sam-on ltd - anastrozole 1 mg - film coated tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

אנסטרוזול מדיטק 1 מ"ג Izrael - hebrejski - Ministry of Health

אנסטרוזול מדיטק 1 מ"ג

sam-on ltd - anastrozole 1 mg - film coated tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

אפיפואם Izrael - hebrejski - Ministry of Health

אפיפואם

megapharm ltd - hydrocortisone acetate; pramocaine hydrochloride - קצף - pramocaine hydrochloride 0.9363 %w/w; hydrocortisone acetate 0.9363 %w/w - relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

לטרוזול טבע  Izrael - hebrejski - Ministry of Health

לטרוזול טבע

teva israel ltd - letrozole - טבליה - letrozole 2.5 mg - letrozole

ויגהמוקס Izrael - hebrejski - Ministry of Health

ויגהמוקס

novartis israel ltd - moxifloxacin as hydrochloride - תמיסה לעין - moxifloxacin as hydrochloride 0.5 % - moxifloxacin - moxifloxacin - for the treatment of bacterial conjunctivitis caused by susceptible strains or organisms.

פרוקטופואם H.C Izrael - hebrejski - Ministry of Health

פרוקטופואם h.c

megapharm ltd - hydrocortisone acetate; pramocaine hydrochloride - קצף - hydrocortisone acetate 1 %; pramocaine hydrochloride 1 % - hydrocortisone

אקסמסטאן טבע  25 מג Izrael - hebrejski - Ministry of Health

אקסמסטאן טבע 25 מג

abic marketing ltd, israel - exemestane - טבליות מצופות פילם - exemestane 25 mg - exemestane - exemestane - exemestane teva® is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane teva® is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies.exemestane teva® is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer following 2-3 years of initial adjuvant tamoxifen therapy

אנאסטרוזול אינובמד 1 מג Izrael - hebrejski - Ministry of Health

אנאסטרוזול אינובמד 1 מג

inovamed ltd - anastrozole - טבליות מצופות פילם - anastrozole 1 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.